The global opioid use disorder treatment market is poised for significant growth, with an expected market size of USD 3.07 billion in 2023 and a projected valuation of USD 8.4 billion by 2033. This growth reflects an impressive compound annual growth rate (CAGR) of 10.5% during the forecast period. As the opioid abuse crisis continues to escalate, the market for OUD treatments is gaining momentum, driven by increased awareness, research advancements, and strategic collaborations.
Raising Awareness to Combat the Opioid Crisis:
One of the key factors propelling the market expansion is the growing awareness about the dangers of opioid abuse and the importance of seeking treatment. Drug abuse treatment providers and manufacturers are increasingly focusing on educating the public, including drug store owners, about the severe effects of drug misuse. Media campaigns through television, newspapers, brochures, and other platforms have proven effective in curbing opioid abuse, broadening the reach of treatment options and directly contributing to the market’s growth.
Strategic Partnerships Fuel Market Growth:
Collaborations between industry leaders and organizations have further bolstered the treatment landscape. Notably, GlaxoSmithKline partnered with 2morrow Inc. in 2016 to offer SmartQuit app users nicotine patches as part of a comprehensive smoking cessation program. Similarly, in 2013, the company teamed up with Amneal Pharmaceuticals to distribute Buprenorphine HCl and Naloxone HCl Dihydrate Sublingual Tablets, a generic version of Suboxone, to addiction treatment centers. Such partnerships are expected to play a critical role in long-term market expansion.
Research & Development Driving Innovation:
As the opioid addiction crisis continues to worsen, the need for integrated research and development into addiction treatment and recovery has grown. Research efforts in addressing opioid use disorder have surged, with stakeholders focusing on translating these findings into real-world care solutions. This ongoing R&D will be a key driver of market growth in the coming years, with the development of new treatment options that better address the needs of individuals struggling with opioid addiction.
Key Market Drivers:
Several factors are fueling the growth of the OUD treatment market, including the rising prevalence of chronic pain-related diseases such as cancer, arthritis, lower back pain, fibromyalgia, and post-surgical pain. Additionally, there is increasing demand for extended-release opioid formulations over immediate-release options, as well as a growing focus on abuse-deterrent formulations (ADF) by generic manufacturers.
Government Initiatives and Mergers & Acquisitions:
In countries like the United Kingdom, public and privately funded programs by the National Health Service (NHS) are playing a vital role in the treatment of opioid use disorder. Furthermore, strategic mergers and acquisitions are enhancing the market’s reach and capabilities. For instance, Acadia Healthcare’s acquisition of Priory Group in December 2015 allowed the company to expand its behavioral care services and geographic presence, further strengthening the OUD treatment market.
Challenges and Outlook:
Despite the positive growth trajectory, challenges remain, notably the rising costs associated with advanced treatment processes. While significant investments in new, medically advanced treatments are essential to boosting recovery rates, the resulting increase in treatment costs poses a challenge to broader market accessibility. Nonetheless, the expanding focus on opioid use disorder treatment, coupled with strategic industry collaborations, is set to overcome these hurdles, ensuring continued market growth.
In conclusion, the global opioid use disorder treatment market is on a robust growth path, supported by rising awareness, strategic collaborations, increasing R&D investment, and governmental initiatives aimed at combating the opioid epidemic. As these factors continue to evolve, the market is expected to witness significant expansion, reaching new heights by 2033.
Key Takeaways:
- North America is expected to dominate the industry while reaching market share of around 48% by the end of the forecast period.
- The market in East Asia is projected to reflect fastest CAGR of 8.8% during the projected timeline.
- By drug class, Buprenorphine is projected to account for 81.4% market share by end of the forecast period.
- Hospitals are expected to dominate the market by distribution channel, with a market share of 35% by 2033.
“Rising collaborations and mergers between companies, increasing research and development activities and adoption of technological advanced techniques for treating Opioid disorder will drive the industry’s growth,” comments an FMI analyst
Rising Demand for Market Data: Our Full Report Offers Deep Insights and Trend Analysis!
Competitive Landscape:
The Opioid use disorder treatment Market is competitive and consists of several major players. Major players are creating novel delivery systems for the treatment of opioid use disorder. This is expected to propel Opioid use disorder treatment market. The major players in the market are: Trevena, Opiate Pharmaceutical, Aphios, Kyowa kirin, Gamida-Cell, Novartis, Titan Pharmaceuticals, Inc., Hikma Pharmaceuticals, MediciNova, Alkermes, Inc., BioDelivery Sciences International, Inc.
Some recent developments in the market are:
- In January 2022, Trevena, Inc. declared that China’s National Medical Products Administration (NMPA) has accepted the submission of a New Drug Application (NDA) for OLINVYK (oliceridine) injection, a novel IV analgesic that has been approved in the United States by the FDA for use in adults for managing acute pain severe enough to require an intravenous opioid analgesic.
- In October 2021, Esteve Pharmaceuticals received authorisation from the United States Food and Drug Administration (FDA) for SEGLENTIS (celecoxib and tramadol hydrochloride) for the management of acute pain in adults that is extreme enough to require an opioid analgesic.
- In January 2020, Titan Pharmaceuticals, Inc. made a revelation that they had entered into an agreement with AllianceRx Walgreens Prime for the expansion of accessibility of patients for Titan’s opioid use disorder implant branded as “Probuphine implant”.
Key Segments Profiled in the Opioid Use Disorder Treatment Market Survey:
By Drug Type:
- Romiplostim
- Omidubicel
- Nalmefene
- Buprenorfine
- Methadone
- Naltrexone
By Route of Administration:
- Oral
- Parenteral
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East & Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
